Lei-jie Dai

Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer.

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer.

Journal: Signal transduction and targeted therapy
Published: October 19, 2025

Omics datasets can bridge the gap between tumor biology and patient care.

Omics datasets can bridge the gap between tumor biology and patient care.

Journal: PLoS biology
Published: July 28, 2025

Evolving molecular subtyping of breast cancer advances precision treatment.

Evolving molecular subtyping of breast cancer advances precision treatment.

Journal: Cancer biology & medicine
Published: September 20, 2024

Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer.

Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer.

Journal: Cancer cell
Published: August 09, 2024

Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies.

Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies.

Journal: Cancer research
Published: December 21, 2023

Next-generation antibody-drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer.

Next-generation antibody-drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer.

Journal: Cancer biology & medicine
Published: October 12, 2023

Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.

Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.

Journal: Nature cancer
Published: December 02, 2022

Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.

Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.

Journal: Nature communications
Published: August 15, 2022

Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.

Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.

Journal: Journal of hematology & oncology
Published: March 14, 2021
Showing 1-9 of 9

Last Updated: 09/26/2026